Kymera: Industry Leader in Developing Oral Degrader Medicines

                                                                                NOVEL INSIGHTS



                                       LEADING CAPABILITIES                 Translation:
                                                                            Deep expertise in targetâ€“drug
                                                                            interplay to optimize drug
  UNIQUE STRATEGIES
                                       Unique Chemistry Capabilities:       disposition and degradation
                                       Finding ligands to historically      across tissues and cell types
Target Selection:                      undrugged targets; designing
Pursuing historically undrugged        degraders with absolute              Accelerated Development:
targets in highly validated            selectivity and atomic level         Leverage learnings and
pathways                               understanding of MOA                 innovation (e.g., new biomarkers,
                                                                            endpoints) from early studies to
Immunology Focus:                      Redefining Drug Development:         inform and derisk mid/late-stage
Building an industry leading           Developed new principles to          development; addressing
pipeline of oral medicines with        match biologics activity with oral   multiple large indications with
biologics-like activity to transform   drugs                                high unmet need
treatments for patients                                                                                         4
